Pharma Companies In China Likely Not Affected By Rising RMB
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Pharmaceutical companies in China are unlikely to be deeply affected by a more expensive renminbi, which has appreciated more rapidly against the dollar and is expected to continue climbing